Orforglipron is an oral medication that is currently being developed for type 2 diabetes and weight loss. It is a GLP-1 that is in early clinical trials.
Effectiveness
Convenience
Form
Tablet
Coming soon
Orforglipron is an oral weight loss medication that is currently being developed for type 2 diabetes and weight loss. It is a GLP-1 tablet in phase 3 of clinical trials and shows results of significant weight loss in patients.
Unlike current GLP-1s (such as Wegovy or Mounjaro), which require weekly injections, orforglipron tablets can be taken once daily without any restrictions on food or water.
It is also being studied as a potential treatment for obstructive sleep apnoea and hypertension in adults with obesity.
Like other GLP-1s, orforglipron imitates a gut hormone. It suppresses appetite, lowers blood glucose levels, and slows gastric emptying. These effects combine to make you feel fuller for longer, causing you to eat less and lose more weight.
The available doses are still being decided. The doses being used in trials start from 1mg and are titrated up to 36mg. The complete list of trial doses is:
Trials have consisted of 1 tablet taken daily, and titrating doses every 4 weeks.
Orforglipron is being developed for the treatment of type 2 diabetes and obesity/weight loss. Clinical trials were done on participants with a BMI of 27 and above, with at least one weight-related comorbidity and a report of at least one self-reported unsuccessful diet to lose weight.
The estimated date for the licensing of orforglipron for weight loss is December 2025.
There is still no mention of prices, as the medication is still not licensed for weight loss. The cost will also vary depending on whether you opt for a private supplier or your GP.
What people are saying
